This week, several stocks caught investors’ attention, driven by significant developments and market momentum. Here’s the breakdown of this week’s trending stocks:
Pulse Biosciences ($PLSE) Jumps After Promising Heart Treatment Results
Pulse Biosciences ($PLSE) is a medical device company working on new ways to treat heart rhythm problems. The company shared new clinical results for its nPulse™ heart catheter, a tool designed to treat atrial fibrillation, a common condition where the heart beats irregularly.
Put simply, the treatment worked better than expected.
In a study of 150 patients, the procedure was successful in all patients checked at 6 months and in almost all patients after one year. The procedure was relatively fast, and serious safety problems were rare. Only two patients had a serious issue related to the treatment, which doctors described as a strong safety result for an early study.
Doctors involved in the trial said the system was easier and quicker to use than many existing approaches, while still delivering long-lasting results. Pulse Biosciences believes this gives the technology a real chance to become a new option for treating atrial fibrillation, and the company plans to move into a larger, more advanced study next.
Pulse’s technology uses very short electrical pulses instead of heat to treat problem heart tissue. The goal is to fix the heart rhythm while avoiding damage to nearby areas.
Stock Price Reaction
$PLSE stock surged 51% after the announcement.
Novo Nordisk ($NVO) Sues Hims & Hers ($HIMS) Over Compounded GLP-1 Drugs
Novo Nordisk ($NVO) has filed a lawsuit against Hims & Hers ($HIMS), accusing the telehealth company of selling unapproved, compounded versions of semaglutide, the key ingredient in Novo Nordisk’s weight-loss and diabetes drugs Wegovy and Ozempic.
In simple terms, Novo Nordisk says Hims is offering knock-off versions of its FDA-approved medicines. According to Novo Nordisk, these compounded products are not reviewed by the FDA, may contain incorrect doses or dangerous impurities, and could pose serious health risks to patients. Novo Nordisk claims its testing found impurity levels as high as 75% to 86% in some compounded semaglutide products.
Novo Nordisk is asking the court to permanently stop Hims from selling these compounded drugs, block what it calls misleading marketing, and seek financial damages. The company also pointed to recent FDA warnings and guidance from medical groups, including the American Diabetes Association, which have advised against using compounded GLP-1 drugs due to safety concerns.
Novo Nordisk added that FDA-approved Wegovy and Ozempic are now fully available in the U.S., arguing that patients no longer need to rely on unapproved alternatives.
Stock Price Reaction
$HIMS shares fell about 6% on the news. $NVO shares closed slightly higher.
Nektar ($NKTR) Shows Long-Lasting Eczema Results
Nektar Therapeutics ($NKTR) said its experimental drug rezpegaldesleukin continued to work well for people with moderate to severe eczema over a full year.
Patients who responded during the initial treatment phase largely maintained their skin improvements through week 52, even when dosing was reduced to monthly or quarterly injections. Importantly, a growing number of patients continued to improve over time, with higher rates of near-complete and complete skin clearance compared with earlier treatment stages.
The safety profile remained consistent with prior results, with no new safety concerns reported. Based on the durability of responses and the ability to use less frequent dosing, the company said the data supports advancing rezpegaldesleukin into pivotal Phase 3 trials.
Stock Price Reaction
$NKTR stock surged about 51% after the announcement.
This article is for informational purposes only and is not investment advice or a solicitation to buy or sell securities. The content is based on publicly available information and reflects the author’s opinions as of the publication date, which may change without notice. All investments carry inherent risks, including the potential loss of principal, and past performance is not indicative of future results. Forward-looking statements, including references to projected revenues, market trends, or business developments, are based on current expectations and assumptions. Actual results may differ due to various factors, including regulatory changes, economic conditions, competitive pressures, and unforeseen market fluctuations. Readers should conduct their own research or consult a financial advisor before making investment decisions. BBAE holds no position in the securities mentioned, nor are they compensated by the companies mentioned.
